I previously posted all of the information about the upcoming 2011 DRI Products Liability Conference here, and I have been asked to post a reminder since we are only a couple of weeks away.
The Defense Research Institute is holding their Products Liability Conference at the Hilton New Orleans Riverside in New Orleans, Louisiana this year from Wednesday, April 6 through Friday, April 8, 2011. This is a great conference. I went to the one last year that was in Las Vegas, and I am attending this year's conference. In fact, I will be presenting on Thursday at one of the Specialized Litigation Group ("SLG") breakout sessions. I joined the "Agricultural/Construction/Mining/Industrial Equipment" ("ACMIE") SLG last year, and this year I am doing a presentation entitled "Who Needs Letterman? The Annual ACMIE Top 10 Cases." As the title suggests, the presentation is basically a survey of significant cases in 2010 that involved ACMIE products and equipment (and if you know of a case that I should consider for inclusion, please comment so that I can get in touch and discuss it with you).
All the details for the conference, including a brochure of the agenda, registration, etc., can be found here. I'm flying in Tuesday for the networking reception that evening, and I look forward to seeing anyone else who will be there.
A blog for individuals and product manufacturers who are interested in South Carolina products liability law. My goal is to provide current information on trends in products liability law in the Palmetto State.
Tuesday, March 22, 2011
Update: South Carolina Attorney General's Lawsuit Against Johnson and Johnson to Begin Jury Deliberations
This is an update to the post below in which I provided an article about the beginning of the South Carolina Attorney General's lawsuit against Johnson & Johnson about the drug Risperdal. According to the article below written by Jef Feeley and Gary Henderson, the jury will begin deliberations in the trial today. The article is a good account of the closing arguments during trial, and the direct link to the article is here. (Thanks to Bloomberg.com for the coverage).
J&J Duped South Carolina Doctors Over Risperdal, Lawyer Says
By Jef Feeley and Gary Henderson - Mar 21, 2011 5:38 PM ET
Johnson & Johnson executives deceived South Carolina doctors about the safety of the antipsychotic drug Risperdal, and the drugmaker should be held liable for that deception, a lawyer said.
J&J made misleading claims about Risperdal’s health risks and effectiveness in a letter to more than 7,000 South Carolina doctors and that violated consumer protection laws, John Simmons, a lawyer for the state, said in closing arguments of the trial of a lawsuit seeking at least $360 million in penalties.
The drugmaker, based in New Brunswick, New Jersey, used “unfair and deceptive acts” in a marketing campaign designed to dupe doctors into signing off on Risperdal for mental-health patients, Simmons told jurors today.
The state’s case centers on drug-safety claims that J&J and its Ortho-McNeil-Janssen Pharmaceuticals unit made in November 2003 correspondence to 700,000 doctors across the U.S., including 7,200 in South Carolina. The U.S. Food and Drug Administration responded with a warning letter saying J&J made false and misleading claims that minimized the potentially fatal risks of diabetes and overstated the drug’s superiority to those from competitors.
J&J contends the state hasn’t proved the company set out to mislead doctors about Risperdal or started a “spin campaign” to bolster sales of the drug, Steven J. Pugh, one of the drugmaker’s lawyers, said in his closing statement.
Fall in Sales
South Carolinians with mental-health issues “have benefited from Risperdal,” Pugh said. “You haven’t heard that anyone in South Carolina has been harmed by Risperdal.”
Risperdal’s global sales peaked at $4.5 billion in 2007 and declined after the company lost patent protection. It generated $3.4 billion in sales in 2008, or 5.4 percent of J&J’s total sales, according to company filings. Sales of the drug fell to $527 million last year, according to a January earnings report.
Risperdal Consta, the long-acting version of the antipsychotic drug, generated $1.5 billion in sales last year for Johnson & Johnson (JNJ), officials said this month.
Under South Carolina’s unfair trade practices law, if jurors decide Johnson & Johnson deceived doctors about Risperdal in the 2003 letter, the company can be fined as much as $5,000 for each letter. Judge Roger Couch will decide the financial- penalty issue after jurors hand down their decision.
Third Jury Trial
The case is the third of about 10 state lawsuits to be considered by jurors over J&J’s Risperdal marketing campaigns. In June, J&J won dismissal of Pennsylvania’s suit alleging the company hid the drug’s diabetes risk and tricked regulators into paying millions more than they should have for the medicine.
A Louisiana jury ordered the drugmaker in October to pay $257.7 million in damages to that state for making misleading claims about Risperdal’s safety. A judge later added $73 million in legal fees to the award.
A West Virginia judge in a 2009 non-jury trial awarded $3.95 million, finding the company misled doctors about the risks and benefits of Risperdal. The state dropped its Risperdal claim after J&J won an appeal, company officials said in February.
J&J’s Risperdal letter to doctors was part of a campaign to protect billions of dollars in sales of the antipsychotic drug and showed a lack of concern for the safety of South Carolina patients who took the drug, Simmons said.
The drugmaker set up a “spin machine” to deceive doctors about the drug and hid studies casting doubt on the medication’s safety and effectiveness, the lawyer said. “It was all about the money,” he added.
‘Send a Message’
“You have the power to send a message to these companies that you can’t hide stuff,” Simmons said. “Tell them, no unethical, immoral conduct in South Carolina.”
The Risperdal letter in the state’s crosshairs isn’t a proper basis for the attorney general’s claims that the drugmaker violated consumer-protection laws, Pugh countered.
The FDA warned J&J in 2004 to correct some things in the letter, but never formally sanctioned the drugmaker for sending it out, the lawyer added.
“The November 2003 letter was true then and it’s true now,” Pugh said. Risperdal is different from other antipsychotic medicines and “doctors needed to know that,” he added.
Jurors will begin deliberating the case tomorrow.
The case is State of South Carolina v. Janssen Pharmaceuticals, 2007-CP-4201438, Circuit Court for Spartanburg County, South Carolina (Spartanburg).
To contact the reporters on this story: Jef Feeley in Wilmington, Delaware, at jfeeley@bloomberg.net Gary Henderson in Spartanburg, South Carolina at wgaryh@gmail.com.
To contact the editor responsible for this story: David E. Rovella at drovella@bloomberg.net.
This post is subject to the DISCLAIMER & TERMS OF USE of this website.
J&J Duped South Carolina Doctors Over Risperdal, Lawyer Says
By Jef Feeley and Gary Henderson - Mar 21, 2011 5:38 PM ET
Johnson & Johnson executives deceived South Carolina doctors about the safety of the antipsychotic drug Risperdal, and the drugmaker should be held liable for that deception, a lawyer said.
J&J made misleading claims about Risperdal’s health risks and effectiveness in a letter to more than 7,000 South Carolina doctors and that violated consumer protection laws, John Simmons, a lawyer for the state, said in closing arguments of the trial of a lawsuit seeking at least $360 million in penalties.
The drugmaker, based in New Brunswick, New Jersey, used “unfair and deceptive acts” in a marketing campaign designed to dupe doctors into signing off on Risperdal for mental-health patients, Simmons told jurors today.
The state’s case centers on drug-safety claims that J&J and its Ortho-McNeil-Janssen Pharmaceuticals unit made in November 2003 correspondence to 700,000 doctors across the U.S., including 7,200 in South Carolina. The U.S. Food and Drug Administration responded with a warning letter saying J&J made false and misleading claims that minimized the potentially fatal risks of diabetes and overstated the drug’s superiority to those from competitors.
J&J contends the state hasn’t proved the company set out to mislead doctors about Risperdal or started a “spin campaign” to bolster sales of the drug, Steven J. Pugh, one of the drugmaker’s lawyers, said in his closing statement.
Fall in Sales
South Carolinians with mental-health issues “have benefited from Risperdal,” Pugh said. “You haven’t heard that anyone in South Carolina has been harmed by Risperdal.”
Risperdal’s global sales peaked at $4.5 billion in 2007 and declined after the company lost patent protection. It generated $3.4 billion in sales in 2008, or 5.4 percent of J&J’s total sales, according to company filings. Sales of the drug fell to $527 million last year, according to a January earnings report.
Risperdal Consta, the long-acting version of the antipsychotic drug, generated $1.5 billion in sales last year for Johnson & Johnson (JNJ), officials said this month.
Under South Carolina’s unfair trade practices law, if jurors decide Johnson & Johnson deceived doctors about Risperdal in the 2003 letter, the company can be fined as much as $5,000 for each letter. Judge Roger Couch will decide the financial- penalty issue after jurors hand down their decision.
Third Jury Trial
The case is the third of about 10 state lawsuits to be considered by jurors over J&J’s Risperdal marketing campaigns. In June, J&J won dismissal of Pennsylvania’s suit alleging the company hid the drug’s diabetes risk and tricked regulators into paying millions more than they should have for the medicine.
A Louisiana jury ordered the drugmaker in October to pay $257.7 million in damages to that state for making misleading claims about Risperdal’s safety. A judge later added $73 million in legal fees to the award.
A West Virginia judge in a 2009 non-jury trial awarded $3.95 million, finding the company misled doctors about the risks and benefits of Risperdal. The state dropped its Risperdal claim after J&J won an appeal, company officials said in February.
J&J’s Risperdal letter to doctors was part of a campaign to protect billions of dollars in sales of the antipsychotic drug and showed a lack of concern for the safety of South Carolina patients who took the drug, Simmons said.
The drugmaker set up a “spin machine” to deceive doctors about the drug and hid studies casting doubt on the medication’s safety and effectiveness, the lawyer said. “It was all about the money,” he added.
‘Send a Message’
“You have the power to send a message to these companies that you can’t hide stuff,” Simmons said. “Tell them, no unethical, immoral conduct in South Carolina.”
The Risperdal letter in the state’s crosshairs isn’t a proper basis for the attorney general’s claims that the drugmaker violated consumer-protection laws, Pugh countered.
The FDA warned J&J in 2004 to correct some things in the letter, but never formally sanctioned the drugmaker for sending it out, the lawyer added.
“The November 2003 letter was true then and it’s true now,” Pugh said. Risperdal is different from other antipsychotic medicines and “doctors needed to know that,” he added.
Jurors will begin deliberating the case tomorrow.
The case is State of South Carolina v. Janssen Pharmaceuticals, 2007-CP-4201438, Circuit Court for Spartanburg County, South Carolina (Spartanburg).
To contact the reporters on this story: Jef Feeley in Wilmington, Delaware, at jfeeley@bloomberg.net Gary Henderson in Spartanburg, South Carolina at wgaryh@gmail.com.
To contact the editor responsible for this story: David E. Rovella at drovella@bloomberg.net.
This post is subject to the DISCLAIMER & TERMS OF USE of this website.
Wednesday, March 9, 2011
South Carolina Attorney General's Lawsuit Against Johnson and Johnson
Apparently the State's lawsuit against Johnson and Johnson began yesterday. Stephen Largen at the Spartanburg Herald Journal ran the below article yesterday, and you can find the direct link here. A cut and paste of it is below. This lawsuit sounds a good bit like the one against Eli Lilly, which I blogged about here and here awhile back. It includes allegations of off-label promotion and overcharging. I will try to keep my eyes out for coverage of the trial in the papers.
SC's lawsuit vs. Johnson & Johnson goes to trial
By Stephen Largen
stephen.largen@shj.com
Published: Tuesday, March 8, 2011 at 3:15 a.m.
Last Modified: Monday, March 7, 2011 at 9:58 p.m.
Nearly four years after the state of South Carolina first sued Johnson & Johnson over claims a subsidiary company overcharged the state for an antipsychotic drug and hid the risk of its side effects, the trial will begin this morning in 7th Judicial Circuit Court.
A jury, which will decide liability in the case but leave the awarding of any potential monetary damages to Judge Roger Couch, was seated Monday.
The S.C. Attorney General’s Office claims in its lawsuit that J&J’s Titusville, N.J.-based Janssen unit improperly marketed the drug Risperdal for unapproved uses, including treating children and dementia patients, dramatically overcharged the state for the drug, and did not adequately disclose the risk to patients of diabetes and other side effects.
A lawsuit represents only one side of a legal argument.
The S.C. Department of Health and Human Services paid about $10 million annually for a decade to provide the drug for Medicaid recipients.
Risperdal hit the market in 1994, and by 2008 generated $3.4 billion in sales.
Attorneys for the state aim to prove that the massive sales figures were due in large part to aggressive, deceptive marketing.
Two other states that made similar claims against J&J have won monetary awards, while another had its case dismissed.
Last fall, Louisiana was awarded $257 million in damages. Two years ago, West Virginia was awarded $4.4 million.
Pennsylvania had its case dismissed last summer.
Several other states have pending Risperdal claims against J&J.
South Carolina filed a similar fraudulent-marketing lawsuit against drugmaker Eli Lilly related to the marketing of its antipsychotic drug Zyprexa, and it settled with the company for $45 million in 2009.
The state’s representation in the J&J case includes attorneys who worked on the Eli Lilly case and Risperdal cases in other states.
The Risperdal trial is scheduled to open at 9 a.m. today. The trial is expected to last three weeks.
This post is subject to the DISCLAIMER & TERMS OF USE of this website.
SC's lawsuit vs. Johnson & Johnson goes to trial
By Stephen Largen
stephen.largen@shj.com
Published: Tuesday, March 8, 2011 at 3:15 a.m.
Last Modified: Monday, March 7, 2011 at 9:58 p.m.
Nearly four years after the state of South Carolina first sued Johnson & Johnson over claims a subsidiary company overcharged the state for an antipsychotic drug and hid the risk of its side effects, the trial will begin this morning in 7th Judicial Circuit Court.
A jury, which will decide liability in the case but leave the awarding of any potential monetary damages to Judge Roger Couch, was seated Monday.
The S.C. Attorney General’s Office claims in its lawsuit that J&J’s Titusville, N.J.-based Janssen unit improperly marketed the drug Risperdal for unapproved uses, including treating children and dementia patients, dramatically overcharged the state for the drug, and did not adequately disclose the risk to patients of diabetes and other side effects.
A lawsuit represents only one side of a legal argument.
The S.C. Department of Health and Human Services paid about $10 million annually for a decade to provide the drug for Medicaid recipients.
Risperdal hit the market in 1994, and by 2008 generated $3.4 billion in sales.
Attorneys for the state aim to prove that the massive sales figures were due in large part to aggressive, deceptive marketing.
Two other states that made similar claims against J&J have won monetary awards, while another had its case dismissed.
Last fall, Louisiana was awarded $257 million in damages. Two years ago, West Virginia was awarded $4.4 million.
Pennsylvania had its case dismissed last summer.
Several other states have pending Risperdal claims against J&J.
South Carolina filed a similar fraudulent-marketing lawsuit against drugmaker Eli Lilly related to the marketing of its antipsychotic drug Zyprexa, and it settled with the company for $45 million in 2009.
The state’s representation in the J&J case includes attorneys who worked on the Eli Lilly case and Risperdal cases in other states.
The Risperdal trial is scheduled to open at 9 a.m. today. The trial is expected to last three weeks.
This post is subject to the DISCLAIMER & TERMS OF USE of this website.
Friday, March 4, 2011
Voila!
The kind people in the marketing and IT departments here at Collins & Lacy, P.C. have been helping me with a "bold, fresh new look." I am not sure how "bold" or "fresh" a legal blog can be, but we strive for excellence here at the South Carolina Products Liability Law Blog. I hope you enjoy the updated look, and comments are always welcome. I am also going to add a new blogroll and update some links, so check in from time to time.
Wednesday, March 2, 2011
More on the Legislative Amendment to Overturn Branham v. Ford
I wanted to provide an update on the post below concerning the proposed amendment to reverse the holding in Branham v. Ford. Admittedly, I was not at the hearing in question, and all the information I had at the time of my post was through the grapevine and from the article in the South Carolina Chamber of Commerce Update. Since my post, I have learned that the bill in question is H.B. 3375, which is entitled the "South Carolina Fairness in Civil Justice Act of 2011." At the hyperlink, you can find the various versions of the bill, by date. The version with the amendment in question is here, which is the committee report from February 23, 2011.
As you read through it, you are not going to find language that says "hey, this is the part that reverses Branham v. Ford." Instead, the amendment is more subtle. It strikes Sections 15-73-10, 20 and 30 of the South Carolina Code and adopts identical Sections 15-73-11, 21 and 31. My understanding is that the expressed purpose of the amendment was to overturn Branham. I am told that at the hearing, it was stated that the Branham case stood for the principle that if the Legislature did not actively renew a statue after a number of years, the Supreme Court felt it was empowered to overturn statutory authority and to adopt a rule of law directly contrary to the statute. Therefore, the amendment is to "renew" the statutory authority. The amendment re-adopts the comments to Section 402A of the Restatement (Second) of Torts as new Section 15-73-31.
My brief of Branham discusses how the South Carolina Supreme Court addressed the evolution of products liability law since incorporation of comment 402A into the statute, including the Restatement (Third) of Torts: Products Liability in 1998. The Restatement (Third) and the majority of jurisdictions have evolved toward the risk-utility test for design defect cases, and South Carolina's appellate courts have also gravitated toward this test over the years. Therefore, it makes sense to adopt it as the test for design defect cases. I do not read Branham as some sort of judicial slap to the face of the statutory authority or the Legislature. Rather, it is an attempt to keep South Carolina current in products liability law. However, I welcome reader comments.
This post is subject to the DISCLAIMER AND TERMS OF USE of this website.
As you read through it, you are not going to find language that says "hey, this is the part that reverses Branham v. Ford." Instead, the amendment is more subtle. It strikes Sections 15-73-10, 20 and 30 of the South Carolina Code and adopts identical Sections 15-73-11, 21 and 31. My understanding is that the expressed purpose of the amendment was to overturn Branham. I am told that at the hearing, it was stated that the Branham case stood for the principle that if the Legislature did not actively renew a statue after a number of years, the Supreme Court felt it was empowered to overturn statutory authority and to adopt a rule of law directly contrary to the statute. Therefore, the amendment is to "renew" the statutory authority. The amendment re-adopts the comments to Section 402A of the Restatement (Second) of Torts as new Section 15-73-31.
My brief of Branham discusses how the South Carolina Supreme Court addressed the evolution of products liability law since incorporation of comment 402A into the statute, including the Restatement (Third) of Torts: Products Liability in 1998. The Restatement (Third) and the majority of jurisdictions have evolved toward the risk-utility test for design defect cases, and South Carolina's appellate courts have also gravitated toward this test over the years. Therefore, it makes sense to adopt it as the test for design defect cases. I do not read Branham as some sort of judicial slap to the face of the statutory authority or the Legislature. Rather, it is an attempt to keep South Carolina current in products liability law. However, I welcome reader comments.
This post is subject to the DISCLAIMER AND TERMS OF USE of this website.
Friday, February 25, 2011
Something is afoot at the Legislature...(Update on Branham v. Ford and Proposed Punitive Damages Cap)
I have been hearing for awhile that there is a chance that the South Carolina State Legislature may take action in response to the South Carolina Supreme Court's decision in Branham v. Ford, and these rumors (may have been) confirmed today.
Apparently Senator Brad Hutto has offered an amendment to repeal the holding in the case. I say "may have been" above because I have not obtained a copy of the amendment, but the South Carolina Chamber of Commerce Competitiveness Update talks about this particular issue, and proposed caps on punitive damages, in today's edition. A cut and paste of the article is below (click the hyperlink above for the actual article). I will try to obtain the amendment and determine the nature of the provision.
Trial Lawyers Take Tort Reform Hostage
Last week, a Senate Judiciary subcommittee passed a comprehensive tort reform bill supported by the business community. However, this week the full Senate Judiciary Committee watered down key pieces of tort reform, including a meaningful punitive damage cap. The subcommittee also set unreasonable monetary thresholds for the admissibility of the non-use of seat belts.
The amended bill could be debated on the Senate floor as early as next week, and the South Carolina Chamber of Commerce is asking senators to vote against the committee amendment. If the committee amendment is defeated, the bill will revert back to the House-passed version of tort reform, which is a much stronger, pro-business bill championed by Speaker Bobby Harrell (Charleston).
The South Carolina Chamber and the South Carolina Civil Justice Coalition are also asking senators to examine neighboring states’ punitive damage limits, specifically Virginia, North Carolina, Georgia and Florida, and pick a model. Currently, trial lawyers are picking and choosing words and phrases from the other states in an attempt to render any cap in South Carolina meaningless.
The Chamber is also very concerned with an amendment offered by Senator Brad Hutto (Orangeburg), which was adopted by the full committee and repeals the Branham v Ford decision. The decision places South Carolina in the minority compared with other states on product liability issues. It also weakens the state’s business climate. At a time when the South Carolina Department of Commerce is working to expand the automotive cluster, this amendment must be stripped out of the tort reform bill.
This post is subject to the DISCLAIMER AND TERMS OF USE of this website.
Apparently Senator Brad Hutto has offered an amendment to repeal the holding in the case. I say "may have been" above because I have not obtained a copy of the amendment, but the South Carolina Chamber of Commerce Competitiveness Update talks about this particular issue, and proposed caps on punitive damages, in today's edition. A cut and paste of the article is below (click the hyperlink above for the actual article). I will try to obtain the amendment and determine the nature of the provision.
Trial Lawyers Take Tort Reform Hostage
Last week, a Senate Judiciary subcommittee passed a comprehensive tort reform bill supported by the business community. However, this week the full Senate Judiciary Committee watered down key pieces of tort reform, including a meaningful punitive damage cap. The subcommittee also set unreasonable monetary thresholds for the admissibility of the non-use of seat belts.
The amended bill could be debated on the Senate floor as early as next week, and the South Carolina Chamber of Commerce is asking senators to vote against the committee amendment. If the committee amendment is defeated, the bill will revert back to the House-passed version of tort reform, which is a much stronger, pro-business bill championed by Speaker Bobby Harrell (Charleston).
The South Carolina Chamber and the South Carolina Civil Justice Coalition are also asking senators to examine neighboring states’ punitive damage limits, specifically Virginia, North Carolina, Georgia and Florida, and pick a model. Currently, trial lawyers are picking and choosing words and phrases from the other states in an attempt to render any cap in South Carolina meaningless.
The Chamber is also very concerned with an amendment offered by Senator Brad Hutto (Orangeburg), which was adopted by the full committee and repeals the Branham v Ford decision. The decision places South Carolina in the minority compared with other states on product liability issues. It also weakens the state’s business climate. At a time when the South Carolina Department of Commerce is working to expand the automotive cluster, this amendment must be stripped out of the tort reform bill.
This post is subject to the DISCLAIMER AND TERMS OF USE of this website.
Thursday, February 24, 2011
Case Brief: Salladin v. Tellis
Today's case brief is Salladin v. Tellis, 247 S.C. 267, 146 S.E.2d 875 (1966). This an older, short opinion that reviews the landmark case of MacPherson v. Buick Motor Co., 217 N.Y. 382, 111 N.E. 1050 (1916) and the concept of privity in tort law.
FACTUAL BACKGROUND: The decedent was electrocuted while working in the repair and renovation of a pharmacy in Charleston, South Carolina. 247 S.C. at 269, 146 S.E.2d at 876. As alleged in the Complaint, decedent "came into contact with a highly charged piece of metal." Id.
PROCEDURE: Plaintiff brought a wrongful death lawsuit on behalf of the decedent's estate against numerous defendants. 247 S.C. at 269, 146 S.E.2d at 876. Defendant Universal Manufacturing Corporation ("Defendant"), a manufacturer of electrical transformers and devices, demurred to the Complaint on grounds of lack of privity between Defendant and the decedent. Id. Defendant also argued that the decedent was not a vendee of Defendant's product and was not using the product at the time of his injury. Id. The circuit court overruled the demurrer. Id.
ISSUE(S): Defendant appealed the overruling of the demurrer by the circuit court.
DISPOSITION: The South Carolina Supreme Court affirmed the circuit court's decision.
RULES AND OPINION: The court reviewed the "celebrated decision" in MacPherson v. Buick Motor Co., 217 N.Y. 382, 111 N.E. 1050 (1916) which established that the manufacturer of a product which, when put to its intended use, is imminently dangerous if defective, is liable in tort for negligence in its manufacture. 247 S.C. at 269, 146 S.E.2d at 876. The court noted that the MacPherson case abolished the concept of privity in products liability cases and that a manufacturer's duty extends to anyone who may reasonably be expected to be in the vicinity of a products probable use and to be endangered if the product is defective. Id. at 269-70, 146 S.E.2d at 876-77. The court cited to the following rule as the applicable law for opposing the demurrer:
This post is subject to the DISCLAIMER AND TERMS OF USE of this website.
FACTUAL BACKGROUND: The decedent was electrocuted while working in the repair and renovation of a pharmacy in Charleston, South Carolina. 247 S.C. at 269, 146 S.E.2d at 876. As alleged in the Complaint, decedent "came into contact with a highly charged piece of metal." Id.
PROCEDURE: Plaintiff brought a wrongful death lawsuit on behalf of the decedent's estate against numerous defendants. 247 S.C. at 269, 146 S.E.2d at 876. Defendant Universal Manufacturing Corporation ("Defendant"), a manufacturer of electrical transformers and devices, demurred to the Complaint on grounds of lack of privity between Defendant and the decedent. Id. Defendant also argued that the decedent was not a vendee of Defendant's product and was not using the product at the time of his injury. Id. The circuit court overruled the demurrer. Id.
ISSUE(S): Defendant appealed the overruling of the demurrer by the circuit court.
DISPOSITION: The South Carolina Supreme Court affirmed the circuit court's decision.
RULES AND OPINION: The court reviewed the "celebrated decision" in MacPherson v. Buick Motor Co., 217 N.Y. 382, 111 N.E. 1050 (1916) which established that the manufacturer of a product which, when put to its intended use, is imminently dangerous if defective, is liable in tort for negligence in its manufacture. 247 S.C. at 269, 146 S.E.2d at 876. The court noted that the MacPherson case abolished the concept of privity in products liability cases and that a manufacturer's duty extends to anyone who may reasonably be expected to be in the vicinity of a products probable use and to be endangered if the product is defective. Id. at 269-70, 146 S.E.2d at 876-77. The court cited to the following rule as the applicable law for opposing the demurrer:
A manufacturer who fails to exercise reasonable care in the manufacture of a chattel which, unless carefully made, he should recognize as involving an unreasonable risk of causing physical harm to those who use it for a purpose for which the manufacturer should expect it to be used and to those whom he should expect to be endangered by its probable use, is subject to liability for physical harm caused to them by its lawful use in a manner and for a purpose for which it is supplied.Id. at 271, 146 S.E.2d at 877. Therefore, in this case, it did not matter that the decedent lacked privity and/or was not a vendor of the product.
This post is subject to the DISCLAIMER AND TERMS OF USE of this website.
Labels:
Case Briefs,
Electrical Switches/Devices,
Privity
Wednesday, February 23, 2011
South Carolina Bar "Distance Learning" CLE Presentation on Warnings Law
I have been asked by the South Carolina Bar to do a one hour "Distance Learning" presentation on South Carolina warnings law based on the article I recently had published in South Carolina Lawyer. I guess I did not realize that the Bar offers these types of videotaped programs for CLE credit, but I was very happy to be offered the opportunity to do it.
We have tentatively scheduled the videotaping for April 19, 2011, but my hope is that we can do it sooner (depending on how some scheduling works out). I intend to cover much of the material written about in South Carolina Lawyer article. However, because of space constraints for that particular article, I had to cut out much of the text relating to limitations on the duty to warn in South Carolina (I hope to have the material that was cut published as a separate article in the near future). Therefore, this presentation will afford me the opportunity to cover that material, as well.
If there are any lawyers licensed in South Carolina who practice out of state, or any in-state lawyers who just need the convenience of a video CLE, I invite you to be on the lookout for this new addition. I assume you will be able to find it listed here, but will update this post once the presentation goes online.
We have tentatively scheduled the videotaping for April 19, 2011, but my hope is that we can do it sooner (depending on how some scheduling works out). I intend to cover much of the material written about in South Carolina Lawyer article. However, because of space constraints for that particular article, I had to cut out much of the text relating to limitations on the duty to warn in South Carolina (I hope to have the material that was cut published as a separate article in the near future). Therefore, this presentation will afford me the opportunity to cover that material, as well.
If there are any lawyers licensed in South Carolina who practice out of state, or any in-state lawyers who just need the convenience of a video CLE, I invite you to be on the lookout for this new addition. I assume you will be able to find it listed here, but will update this post once the presentation goes online.
Subscribe to:
Posts (Atom)